keyword
MENU ▼
Read by QxMD icon Read
search

Basal insulin dose

keyword
https://www.readbyqxmd.com/read/27930869/efficacy-and-safety-of-premixed-insulin-analogs-in-asian-patients-with-type-2-diabetes-a-systematic-review
#1
Wayne H-H Sheu, Linong Ji, Woo Je Lee, Abdul Jabbar, Jeong Hee Han, Thomas Lew
AIMS/INTRODUCTION: The primary aim of this systematic review was to provide an overview of the efficacy and safety of premixed insulin analogs in Asians, specifically East Asians, with type 2 diabetes. MATERIAL AND METHODS: The MEDLINE, Embase, Cochrane Library, and ClinicalTrials. gov databases were searched from 01 January 1995 to 26 November 2015. Randomized controlled trials involving East Asians with type 2 diabetes treated with any premixed insulin analog were included...
December 8, 2016: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/27918600/treatment-of-type-2-diabetes-with-biphasic-insulin-analogues
#2
Ali A Rizvi
The majority of patients with Type 2 diabetes require insulin therapy for treating hyperglycaemia. There are several regimens available for insulin initiation and maintenance. Insulin analogues have been developed to mimic normal physiology as closely as possible. Biphasic analogues can target both fasting and postprandial hyperglycaemia, with the added advantage of being premixed and thus convenient for the patient. A practical and feasible option is to initiate insulin with one or more biphasic preparations at mealtimes, thus providing both basal and prandial coverage...
2016: Eur Med J Diabetes
https://www.readbyqxmd.com/read/27888561/novel-hepato-preferential-basal-insulin-peglispro-bil-does-not-differentially-affect-insulin-sensitivity-compared-with-insulin-glargine-in-patients-with-type-1-and-type-2-diabetes
#3
Niels Porksen, Helle Linnebjerg, Parag Garhyan, Eric Chen Quin Lam, Mary Pat Knadler, Scott J Jacober, Ulrike Hoevelmann, Leona Plum-Moerschel, Elaine Watkins, Amalia Gastaldelli, Tim Heise
AIMS: Basal insulin peglispro (BIL) is a novel PEGylated basal insulin with a flat pharmacokinetic and glucodynamic profile and reduced peripheral effects, which results in a hepato-preferential action. In Phase 3 trials, patients with T1DM treated with BIL had lower prandial insulin requirements, yet improved prandial glucose control, relative to insulin glargine (GL). We hypothesized that this may be due to an enhanced sensitivity to prandial insulin with BIL resulting from lower chronic peripheral insulin action...
November 26, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27871880/abscisic-acid-enhances-glucose-disposal-and-induces-brown-fat-activity-in-adipocytes-in-vitro-and-in-vivo
#4
Laura Sturla, Elena Mannino, Sonia Scarfì, Santina Bruzzone, Mirko Magnone, Giovanna Sociali, Valeria Booz, Lucrezia Guida, Tiziana Vigliarolo, Chiara Fresia, Laura Emionite, Ambra Buschiazzo, Cecilia Marini, Gianmario Sambuceti, Antonio De Flora, Elena Zocchi
Abscisic acid (ABA) is a plant hormone also present in animals, where it is involved in the regulation of innate immune cell function and of glucose disposal, through its receptor LANCL2. ABA stimulates glucose uptake by myocytes and pre-adipocytes in vitro and oral ABA improves glycemic control in rats and in healthy subjects. Here we investigated the role of the ABA/LANCL2 system in the regulation of glucose uptake and metabolism in adipocytes. Silencing of LANCL2 abrogated both the ABA- and insulin-induced increase of glucose transporter-4 expression and of glucose uptake in differentiated 3T3-L1 murine adipocytes; conversely, overexpression of LANCL2 enhanced basal, ABA- and insulin-stimulated glucose uptake...
November 15, 2016: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/27860499/premixed-insulin-analogue-compared-with-basal-plus-regimen-for-inpatient-glycemic-control
#5
Abraham Edgar Gracia-Ramos, María Del Pilar Cruz-Domínguez, Eduardo Osiris Madrigal-Santillán, José Antonio Morales-González, Eduardo Madrigal-Bujaidar, José Leopoldo Aguilar-Faisal
BACKGROUND: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting. OBJECTIVE: To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D). MATERIALS AND METHODS: A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dL on admission was performed...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27846339/an-evolutionary-perspective-on-basal-insulin-in-diabetes-treatment-innovations-in-insulin-insulin-glargine-u-300
#6
John E Anderson
Rates of confirmed and severe, as well as nocturnal, hypoglycemia are generally lower with insulin glargine U-300 than insulin glargine U-100, thereby reducing an important concern of providers and patients regarding insulin therapy. Although a higher dose of insulin glargine U-300 than U-100 is required in most patients, the observed increase in body weight is small and less than with insulin glargine U-100.
October 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27810995/a-mobile-computerized-decision-support-system-to-prevent-hypoglycemia-in-hospitalized-patients-with-type-2-diabetes-mellitus-lessons-learned-from-a-clinical-feasibility-study
#7
Stephan Spat, Klaus Donsa, Peter Beck, Bernhard Höll, Julia K Mader, Lukas Schaupp, Thomas Augustin, Franco Chiarugi, Katharina M Lichtenegger, Johannes Plank, Thomas R Pieber
BACKGROUND: Diabetes management requires complex and interdisciplinary cooperation of health care professionals (HCPs). To support this complex process, IT-support is recommended by clinical guidelines. The aim of this article is to report on results from a clinical feasibility study testing the prototype of a mobile, tablet-based client-server system for computerized decision and workflow support (GlucoTab®) and to discuss its impact on hypoglycemia prevention. METHODS: The system was tested in a monocentric, open, noncontrolled intervention study in 30 patients with type 2 diabetes mellitus (T2DM)...
November 2, 2016: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/27777901/excess-weight-gain-during-insulin-pump-therapy-is-associated-with-higher-basal-insulin-doses
#8
Claudia Boucher-Berry, Elaine A Parton, Ramin Alemzadeh
BACKGROUND: While higher total daily dose (TDD) of insulin has been associated with excess weight gain on insulin pump therapy, the role of higher total basal dose (TBD) of insulin on weight gain has not been studied. We evaluated the impact of higher TBD on weight gain in relationship to glycosylated hemoglobin (HbA1c), hypoglycemic episodes, and change in body mass index (BMI) z score in a group of pediatric patients with type 1 diabetes mellitus (T1DM). METHODS: One-year data from 91 (54 Female/37 Male) patients (2...
2016: Journal of Diabetes and Metabolic Disorders
https://www.readbyqxmd.com/read/27766795/reduction-of-sulfonylurea-with-the-initiation-of-basal-insulin-in-patients-with-inadequately-controlled-type-2-diabetes-mellitus-undergoing-long-term-sulfonylurea-based-treatment
#9
Yeoree Yang, Jeong Ah Shin, Hae Kyung Yang, Seung Hwan Lee, Seung Hyun Ko, Yu Bae Ahn, Kun Ho Yoon, Jae Hyoung Cho
BACKGROUND: There were a limited number of studies about β-cell function after insulin initiation in patients exposed to long durations of sulfonylurea treatment. In this study, we aimed to evaluate the recovery of β-cell function and the efficacy of concurrent sulfonylurea use after the start of long-acting insulin. METHODS: In this randomized controlled study, patients with type 2 diabetes mellitus (T2DM), receiving sulfonylurea for at least 2 years with glycosylated hemoglobin (HbA1c) >7%, were randomly assigned to two groups: sulfonylurea maintenance (SM) and sulfonylurea reduction (SR)...
October 11, 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/27764979/budget-impact-of-treating-commercially-insured-type-1-and-type-2-diabetes-patients-in-the-united-states-with-insulin-degludec-compared-to-insulin-glargine
#10
James Weatherall, Lisa Bloudek, Sarah Buchs
OBJECTIVE: To quantify the annual budget impact if all United States (US) commercially insured type 1 diabetes mellitus patients on basal-bolus therapy (T1DMBBT), type 2 diabetes mellitus patients on basal-oral therapy (T2DMBOT), and type 2 diabetes mellitus patients on basal-bolus therapy (T2DMBBT) switched from insulin glargine (IGlar) to insulin degludec (IDeg). METHODS: A short-term (1-year) budget impact model was developed to evaluate the costs of IDeg vs...
October 21, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27762088/preventive-effect-of-ipragliflozin-on-nocturnal-hypoglycemia-in-patients-with-type-2-diabetes-treated-with-basal-bolus-insulin-therapy-an-open-label-single-center-parallel-randomized-control-study
#11
Fumitaka Okajima, Tomoko Nagamine, Yuko Nakamura, Naomi Hattori, Hitoshi Sugihara, Naoya Emoto
The efficacy of the administration of sodium-glucose co-transporter 2 inhibitor (SGLT2I) or the co-administration of SGLT2I and dipeptidyl peptidase-4 inhibitor (DPP-4I) to insulin therapy is not well known. Fifty-eight patients with type 2 diabetes, admitted for glycemic control, were randomized to basal-bolus insulin therapy (BBT) alone or BBT plus 50 mg ipragliflozin and/or 20 mg teneligliptin. Insulin doses were adjusted to maintain normal blood glucose levels. Plasma glucose profiles were estimated by continuous glucose monitoring (CGM) before discharge...
October 20, 2016: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/27746408/a-randomized-crossover-study-of-the-efficacy-and-safety-of-switching-from-insulin-glargine-to-insulin-degludec-in-children-with-type-1-diabetes
#12
Tatsuhiko Urakami, Yusuke Mine, Masako Aoki, Misako Okuno, Junichi Suzuki
This study implemented a randomized crossover design to evaluate the efficacy and safety of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in 18 children (11 males, 7 females; age 11.0 ± 0.5 years) with type 1 diabetes. All subjects had previously used IGlar once daily at bedtime. We compared fasting plasma glucose (FPG) and HbA1c levels, frequencies of overall and nocturnal (2200 h - 0659 h) hypoglycemia, and basal insulin dose at the baseline with those measured during a 24-week period during which IGlar or IDeg was administered in combination with pre-meal rapid acting insulin analogues...
October 14, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27723226/reduced-peripheral-activity-leading-to-hepato-preferential-action-of-basal-insulin-peglispro-compared-with-insulin-glargine-in-patients-with-type-1-diabetes
#13
S Mudaliar, R R Henry, T P Ciaraldi, D A Armstrong, P M Burke, J H Pettus, P Garhyan, S L Choi, M P Knadler, E C Q Lam, M J Prince, N Bose, N K Porksen, V P Sinha, H Linnebjerg, S J Jacober
AIMS: Basal insulin peglispro (BIL), a novel PEGylated basal insulin with a large hydrodynamic size, has a delayed absorption and reduced clearance that prolongs the duration of action. The current study compared the effects of BIL and insulin glargine (GL) on endogenous glucose production (EGP), glucose disposal rate (GDR) and lipolysis in patients with type 1 diabetes. MATERIALS AND METHODS: This was a randomized, open-label, four-period, crossover study. Patients received intravenous infusions of BIL and GL, each at two dose levels selected for partial and maximal suppression of EGP, during an 8 to 10 h euglycemic clamp procedure with d-[3-(3) H] glucose...
October 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27710135/pharmacodynamic-and-pharmacokinetic-evaluation-of-insulin-glargine-u300-for-the-treatment-of-type-1-diabetes
#14
Kathryn M Hurren, Jessica L O'Neill
Glargine 300 units/ml (Gla-300) is a novel basal insulin formulation approved in 2015 for the treatment of diabetes. This more concentrated form of glargine causes delayed redissolution from the subcutaneous depot after injection and thus altered action profile. Areas covered: The pharmacokinetics, pharmacodynamics, efficacy, and safety of Gla-300 in patients with type 1 diabetes mellitus (T1DM) will be reviewed. Expert opinion: Gla-300 has a flatter and more prolonged pharmacokinetic profile compared to glargine 100 units/ml (Gla-100), but is less potent on a unit per unit basis...
December 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27709762/pharmacological-properties-of-faster-acting-insulin-aspart-versus-insulin-aspart-in-patients-with-type-1-diabetes-using-continuous-subcutaneous-insulin-infusion-a-randomised-double-blind-crossover-trial
#15
Tim Heise, Eric Zijlstra, Leszek Nosek, Tord Rikte, Hanne Haahr
AIMS: Continuous subcutaneous insulin infusion (CSII) is increasingly used in patients with diabetes. Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with a faster time-action profile. We evaluated the pharmacological characteristics of faster aspart versus IAsp> during CSII. MATERIALS AND METHODS: In this randomised, double-blind, crossover trial, 48 men and women aged 18-64 years with type 1 diabetes mellitus (T1DM) received faster aspart and IAsp as a 0...
October 6, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27696221/a-review-of-insulin-degludec-insulin-aspart-pharmacokinetic-and-pharmacodynamic-properties-and-their-implications-in-clinical-use
#16
Hanne Haahr, Edmond G Fita, Tim Heise
Insulin degludec/insulin aspart (IDegAsp; 70 % IDeg and 30 % IAsp) is a soluble combination of two individual insulin analogues in one product, designed to provide mealtime glycaemic control due to the IAsp component and basal glucose-lowering effect from the IDeg component. The pharmacokinetic and pharmacodynamic characteristics of IDegAsp have been investigated in a series of clinical pharmacology studies with generally comparable designs, methodologies and patient inclusion/exclusion criteria. The glucose-lowering effect profile of IDegAsp during once-daily dosing at steady state shows distinct and clearly separated action from the prandial and basal components of IDegAsp...
October 1, 2016: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/27669747/assessment-of-three-fasting-plasma-glucose-targets-for-insulin-glargine-based-therapy-in-people-with-type-2-diabetes-mellitus-in-china-study-protocol-for-a-randomized-controlled-trial
#17
Wenying Yang, Zhaojun Yang, Jing Zhao, Hai Lu, Tianhong Luo
BACKGROUND: A large proportion of patients with T2DM in China do not meet accepted HbA1c targets despite the availability of guidelines that describe a treatment pathway for achieving glycemic control. The aim of this study is to identify the fasting plasma glucose (FPG) target that will provide the highest control rate of HbA1c <7 % in Chinese patients with T2DM treated with an insulin glargine-based regimen as an adjunct to an established OAD regimen. This information will support improvements in diabetes care management in China...
September 26, 2016: Trials
https://www.readbyqxmd.com/read/27660663/insulin-lispro-low-mixture-twice-daily-vs-basal-insulin-glargine-once-daily-and-prandial-insulin-lispro-once-daily-as-insulin-intensification-strategies-in-patients-with-type-2-diabetes-latin-american-subpopulation-analysis-of-a-randomized-trial
#18
Arturo Rojas, Georgina Sposetti, Jorge L Gross, Douglas Eugenio Barbieri, Ran Duan, Bruno Linetzky, Janaina Martins De Lana, Oded Stempa, Angel Rodriguez
BACKGROUND: This post hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation with type 2 diabetes mellitus (T2DM). METHODS: A phase 4, randomized, open-label, parallel-arm trial included participants aged 18-75 years with T2DM taking once-daily insulin glargine and stable doses of metformin and/or pioglitazone with glycated hemoglobin (HbA1c) 7...
2016: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/27658921/initiation-and-intensification-strategies-in-type-2-diabetes-management-a-comparison-of-basal-plus-and-premix-regimens
#19
REVIEW
Michelle Downie, Gary Kilov, Jencia Wong
: The progressive nature of type 2 diabetes (T2D) often results in the need for initiation and subsequent intensification of insulin treatment to achieve glycemic control. The aim of this review is to examine published clinical evidence that has directly compared two recommended treatment approaches in patients with T2D: (1) a 'basal plus' regimen, whereby 1-2 injections of prandial insulin are added to basal insulin; or (2) the use of once- or twice-daily premix insulin analogs, which contain both basal and prandial insulin in a single injection...
December 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27651111/quantifying-rates-of-glucose-production-in-vivo-following-an-intraperitoneal-tracer-bolus
#20
Sheng-Ping Wang, Dan Zhou, Zuliang Yao, Santhosh Satapati, Ying Chen, Natalie A Daurio, Aleksandr Petrov, Xiaolan Shen, Daniel Metzger, Wu Yin, Andrea R Nawrocki, George J Eiermann, Joyce Hwa, Craig Fancourt, Corin Miller, Kithsiri Herath, Thomas P Roddy, Deborah Slipetz, Mark D Erion, Stephen F Previs, David E Kelley
Aberrant regulation of glucose production makes a critical contribution to the impaired glycemic control that is observed in type 2 diabetes. Although isotopic tracer methods have proven to be informative in quantifying the magnitude of such alterations, it is presumed that one must rely on venous access to administer glucose tracers which therein presents obstacles for the routine application of tracer methods in rodent models. Since intraperitoneal injections are readily used to deliver glucose challenges and/or dose potential therapeutics, we hypothesized that this route could also be used to administer a glucose tracer...
December 1, 2016: American Journal of Physiology. Endocrinology and Metabolism
keyword
keyword
32684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"